Drug Channels

MARCH 18, 2024

Informa Connect’s Life Sciences Pricing & Contracting USA May 21-23, 2024 | New Orleans Drug Channels readers save 10% with code 24DRCH10* Whether your daily focus is on Medicaid, Government Pricing, 340B, Drug Price Transparency, Commercial Contracting or Chargebacks , we have you covered!

Drug Pricing 76

Drug Pricing 76

Drug Channels

DECEMBER 15, 2023

This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2024 live video webinar. My topic #9 for 2024: The Battle Over 340B Gets Even Messier. Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. billion —an astonishing $9.8 billion (+$2.6

Drug Pricing 80

Drug Pricing Hospitals 80

Drug Channels

JULY 5, 2022

Fein as he helps you and your team stay on top of the latest trends, market data, and strategies for specialty drugs. He will draw from exclusive information found in DCI’s industry economic reports. PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions.

Drug Pricing 84

Drug Pricing 84

Drug Channels

NOVEMBER 9, 2022

Fein will share his latest thinking on a wide range of topics, including: Retail and specialty pharmacy trends Vertical integration and consolidation The Inflation Reduction Act of 2022 The Medicare Part D Redesign Biosimilars Discount cards and cash-pay pharmacies The growing impact of hospitals and health systems The 340B Drug Pricing Program Federal (..)

Specialty Pharmacies 79

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 79

Pharmaceutical Technology

MAY 17, 2023

The Inflation Reduction Act, which became US law in August 2022, has invited its fair share of critics and supporters over its drug pricing provisions. While negotiating drug prices is common practice in other major markets, CMS had not previously held the legal authority to do so.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Drug Channels

OCTOBER 22, 2020

Below is a brief video primer on a hot Drug Channels topic. I review: The growth of the 340B Drug Pricing Program The role and expansion of 340B contract pharmacies How 340B intersects with the Medicaid drug rebate program Challenges with duplicate discounts This 10 minute video provides a quick and efficient primer on the key issues.

Drug Pricing 52

Drug Pricing 52

Drug Channels

NOVEMBER 14, 2023

Fein will share his latest thinking and projections on a wide range of topics, including: Commercial implications of the Inflation Reduction Act Vertical integration and consolidation trends Update on Humira biosimilars PBM strategies and the outlook for state and federal legislation What’s next for discount cards and cash-pay pharmacies Impact of (..)

Drug Pricing 75

Drug Pricing Biosimilars 75

Drug Channels

FEBRUARY 21, 2023

On March 14, 2023, Drug Channels Institute will release The 2023 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2023 edition at special discounted prices. A new Section 12.5.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars 75

Safe Biologics

NOVEMBER 12, 2023

The event will convene patients, providers, policymakers and advocates to discuss a number of topics impacting the health care space and will be held at the Mayflower Hotel in Washington D.C. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Drug Channels

JULY 17, 2023

Sessions include coverage on multiple hot topics, including: CMS Stacking Rule Everything IRA and 304B FSS and Government Contracting GTN Best Practices State Drug Price Transparency and Reporting Value Based Agreements Bundling, Acquisitions and Divestitures AMP Cap Removal Rebates, Disputes and GP Calculations OIG Perspective on Prescription Drug (..)

Drug Pricing 40

Drug Pricing 40

Safe Biologics

DECEMBER 3, 2023

The most recen t of the webinars, hosted July 29th, examined the negative impact of the Inflation Reducation Act’s Medicare drug price setting provisions. The webinar was the fourth in a series covering key health policy issues. Learn more about ACR Convergence 2023 here.

Biosimilars 130

Biosimilars Labelling Drug Pricing Packaging 130

Pharmaceutical Technology

APRIL 20, 2023

As of 1 April 2023, Japan’s latest ‘off-year’ National Health Insurance (NHI) drug price revisions for FY2023 have now come into effect. While roughly 100 drugs received additional price premiums, the majority of products saw their price reduced as a result of discrepancies between their NHI and market prices.

Drug Pricing 52

Drug Pricing Biosimilars 52

Drug Channels

JUNE 8, 2021

The 340B Drug pricing Program is a crucial topic for pharmacists. For a deep dive, join me for DCI’s upcoming live video webinar, Drug Channels Update: 340B Controversies and Outlook , on June 25, 2021, from 12:00 p.m. A word of caution: These data were collected during the peak of last year’s pandemic shutdowns.

Hospitals 52

Hospitals Physician Offices Drug Pricing 52

Drug Channels

APRIL 19, 2021

Join the compliance community for dynamic discussions on the top risk areas for specialty pharmaceutical companies, including speaker programs, patient support programs, charitable donations, specialty pharmacy relationships, patient advocacy group interactions, mergers and acquisitions, medical affairs activities, drug pricing, transparency and more! (..)

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 40

Drug Channels

NOVEMBER 15, 2021

The Outlook 2022 marks our third annual outlook webinar.

Specialty Pharmacies 66

Specialty Pharmacies Drug Pricing Biosimilars 66

Drug Channels

OCTOBER 15, 2023

Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to November 10, 2023.*

Drug Pricing 55

Drug Pricing Biosimilars 55

Safe Biologics

JANUARY 12, 2024

Coming in January: ASBM Whitepaper on Negative Impacts of Medicare Part D Price Setting In January, the Generics and Biosimilars Initiative (GaBI) will publish a whitepaper entitled Medicare Drug Price Negotiations: Impact on Healthcare Development and Patient Access to Medicines.

Biosimilars 130

Biosimilars Drug Pricing 130

Drug Channels

MARCH 28, 2022

The Medicaid & GP Congress features coverage on the hottest topics impacting you today, from speakers representing United Therapeutics, AstraZeneca, Pfizer, Gilead, GSK, Eisai, Novartis, Vertex and more!

Drug Pricing 66

Drug Pricing 66

Drug Channels

NOVEMBER 30, 2020

Medicaid and Government Pricing Congress. With drug pricing and benefit coverage top of mind for many Americans, coupled with a volatile election and overall healthcare landscape, the stakes are incredibly high for bio/pharma manufacturers. December 14-17, 2020 | Virtual www.informaconnect/medicaidgov.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 13, 2023

Informa Connect is also thrilled that this year's Congress is part of Pricing & Contracting USA! View the agenda for Medicaid & GP 2023 to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/medicaid-government-pricing for further details and to register.

Drug Pricing 66

Drug Pricing 66

Putting Patients First Blog

SEPTEMBER 21, 2023

Significant initiatives being undertaken by CMS and OPOLE include behavioral health, drug price affordability, maternity care, Medicaid unwinding, and rural health.

Drug Pricing 52

Drug Pricing 52

Drug Channels

SEPTEMBER 20, 2021

Drug Channels readers will save 10% off when they use code 21DRCH10 and register prior to October 20th.*.

Drug Pricing 65

Drug Pricing 65

Pharma Marketing Network

JULY 25, 2023

This means targeting your ads to people who have shown interest in certain topics or activities. For example, if you sell a drug that treats a specific condition, you could target your ads to people who have searched for information about that condition. Use interests: You can also target your ads based on interests.

Drug Pricing 98

Drug Pricing 98

Drug Channels

AUGUST 9, 2021

Impactful Sessions Include: Policy Proposals from the Current Administration, House and Senate: What Can We Expect for 2021 and How Will It Impact You?

Drug Pricing 40

Drug Pricing 40

Pharmaceutical Technology

DECEMBER 27, 2022

Drug pricing was a hot-button topic, and William Newton found that while e-commerce chains could cut insulin prices , any major change won’t happen overnight. A few months later, the monkeypox outbreak showed the difficulty in accessing vaccines and antivirals despite a plan to stockpile them.

Vaccines 122

Vaccines Drug Development Drug Pricing 122

Proxsys Rx

DECEMBER 11, 2023

We’ve expressed our own strong opinions on the topic in several blog posts, including this one. For a more comprehensive list of specialty drugs not subject to 340B manufacturer restrictions, please feel free to contact us. For more information on any of the topics discussed in this article, contact Howard Hall.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Compounding 52

Drug Channels

APRIL 11, 2021

Drug Channels readers save 10% off the current registration rate with promo code 21PSSDC10.* Register today.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing 40

Drug Channels

MARCH 19, 2023

NEW THIS YEAR!

Drug Pricing 57

Drug Pricing 57

pharmaphorum

JANUARY 13, 2023

Some will simply raise drug prices to get more money out of new drugs while they can; others are planning to phase in new indications in order to “reset the clock” as many times as they can. “We need to fix this fast, or else there is going to be more legislation that is going to target us.

Drug Pricing 98

Drug Pricing Immunity Immunization Vaccines 98

Proxsys Rx

MARCH 1, 2024

We’ve expressed our own strong opinions on the topic in several blog posts, including this one. For a more comprehensive list of specialty drugs not subject to 340B manufacturer restrictions, please feel free to contact us. For more information on any of the topics discussed in this article, contact Howard Hall.

Specialty Pharmacies 40

Specialty Pharmacies Hospitals Drug Pricing Compounding 40

Pharma in Brief

JANUARY 10, 2024

Expected highlights for 2024 include a final PTA regime, more details on PMPRB drug pricing guidelines and national pharmacare, and fall-out from the US mass drug importation program targeting Canadian medicines. The employee count cut-off in all small entity definitions has increased from 50 to fewer than 100.

Drug Pricing 52

Drug Pricing Documentation Biosimilars Vaccines 52

Safe Biologics

FEBRUARY 1, 2024

It examines the likely negative effects of IRA’s price negotiation provisions, which allow the Centers for Medicare and Medicaid Services to negotiate prices of certain costly drugs, including many biologic medicines.

Biosimilars 130

Biosimilars Documentation Drug Pricing 130

STAT

FEBRUARY 9, 2023

What I found interesting — and symbolic of the health policy dilemma facing the United States — was how these topics were disconnected in the speech. Early in the speech, the president said , “And we’re finally giving Medicare the power to negotiate drug prices.”

Drug Pricing 198

Drug Pricing Drug Development 198

Pharma Leaders

JUNE 1, 2023

Each business day, FDAnews provides valuable insights into: Best practices in regulatory compliance and the pathways to approval Draft and final guidances from the FDA and other regulatory agencies Company mergers and technology developments FDA budgets and spending, including proposals and approvals by Congress and the President Quality and GMP regulatory (..)

Drug Pricing 40

Drug Pricing Documentation 40

Viseven

JANUARY 13, 2023

So, at the end of the day, the HEOR’s major task is to make sure that the patients who get access to the new treatment will get the best health outcomes at the most affordable price. HEOR Impact on Drug Pricing and Marketing. Naturally, HEOR experts take part in the pre-dev stages and assess the process at all following stages.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Dosage Drug Pricing 40

PharmaShots

MARCH 30, 2023

In return, greater access to a more diverse patient population fills studies more quickly, extending patent life, which leads to greater sponsor profitability, and even lower drug prices. Morgan Healthcare conference to speak with investors and elaborate further on the FDA guidance topic.

Drug Pricing 40

Drug Pricing Hospitals 40

STAT

MARCH 8, 2024

But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of (..)

Drug Pricing 230

Drug Pricing Drug Development 230